

Effects of conjugated linoleic acid on growth, non-specific immunity, antioxidant capacity, lipid deposition and related gene expression in juvenile large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets

Rantao Zuo, Qinghui Ai*, Kangsen Mai and Wei Xu

The Key Laboratory of Mariculture (Ministry of Education of China), Ocean University of China, 5 Yushan Road, Qingdao, Shandong 266003, People's Republic of China

(Submitted 7 September 2012 – Final revision received 1 December 2012 – Accepted 14 January 2013 – First published online 4 March 2013)

Abstract

The effects of conjugated linoleic acid (CLA) on growth performance, non-specific immunity, antioxidant capacity, lipid deposition and related gene expression were investigated in the large yellow croaker (*Larimichthys crocea*). Fish (7.56 (SEM 0.60) g) were fed soyabean oil-based diets with graded levels of CLA (0, 0.42, 0.83, 1.70%) for 70 d. Quantitative PCR was used to assess the effects of CLA on the transcription of inflammation- and fatty acid oxidation-related genes. Growth in fish fed the diet with 0.42% CLA was significantly higher. Also, phagocytic index and respiratory burst activity were significantly higher in fish fed the diets containing 0.42 and 0.83% CLA, respectively. Hepatic total antioxidative capacity and catalase activities increased significantly when CLA increased from 0 to 0.83%, and then decreased with further increase of CLA. However, hepatic malondialdehyde content decreased significantly as dietary CLA increased. Lipid concentration in the whole body and muscle increased significantly with increasing dietary CLA. Transcription of genes related to inflammation (cyclo-oxygenase-2 and IL- β) in the liver and kidney and fatty acid oxidation (carnitine palmitoyl transferase I and acyl CoA oxidase) in the kidney decreased significantly as dietary CLA increased. PPAR α and acyl CoA oxidase expression in the liver decreased significantly as CLA increased from 0.42 to 1.70%. These results strongly suggest that dietary CLA could significantly affect growth performance, non-specific immunity, antioxidant capacity, lipid deposition and transcription of inflammation- and fatty acid oxidation-related genes of the large yellow croaker. This may contribute to our understanding of the mechanisms related to the physiological effects of dietary CLA in fish.

Key words: Conjugated linoleic acid: Non-specific immunity: Antioxidative capacity: Gene expression

Conjugated linoleic acid (CLA) is a collective term for isomers of linoleic acid (18:2n-6) and the two main isomers are *cis*-9, *trans*-11 and *trans*-10, *cis*-12⁽¹⁾. In mammals, CLA has been shown to exert potential health benefits related to its antioxidative, anticarcinogenic, immunomodulative and diabetes-modulator properties in addition to decreasing body fat deposition^(2–4). In the last decade, studies have been conducted to investigate the effects of CLA on growth performance, liver lipid deposition, non-specific immunity as well as deposition of this fatty acid in a variety of freshwater fish species including channel catfish (*Ictalurus punctatus*), tilapia (*Oreochromis niloticus*), rainbow trout (*Oncorhynchus mykiss*) and yellow catfish (*Pelteobagrus fulvidraco*), and

some euryhaline fish species, such as sea bass (*Dicentrarchus labrax*), yellow perch (*Perca flavescens*) and Atlantic salmon (*Salmo salar*)^(4–11). It has been shown that fish are capable of accumulating high levels of CLA in their tissues when diets are supplemented with this particular fatty acid⁽¹²⁾. However, as for growth performance and liver lipid deposition, results vary significantly among different fish species. It has been shown that growth performance is not significantly affected by the inclusion of CLA up to 1% in juvenile sea bass⁽⁴⁾ and Atlantic salmon⁽¹⁰⁾, or 2% in channel catfish⁽⁷⁾. However, growth performance was significantly decreased by CLA at the level of 1% in hybrid striped bass (*Morone saxatilis* × *Morone chrysops*)⁽⁶⁾ and yellow catfish⁽¹¹⁾, and by

Abbreviations: ACO, acyl CoA oxidase; ARA, arachidonic acid; CAT, catalase; cDNA, complementary DNA; CLA, conjugated linoleic acid; COX-2, cyclo-oxygenase-2; CPT1, carnitine palmitoyl transferase I; HUFA, highly unsaturated fatty acid; MDA, malondialdehyde; PI, phagocytic index; TFA, total fatty acids.

* **Corresponding author:** Q. Ai, fax +86 532 82031943, email qhai@ouc.edu.cn

2% in gilthead sea bream (*Sparus aurata* L.)⁽¹⁾ and tilapia⁽¹³⁾. Growth-promoting effects by dietary CLA have also been reported, with weight gain of common carp (*Cyprinus carpio*) and channel catfish increased by the level of 1% CLA^(14,15). Similar variation has been found in lipid deposition in response to increasing dietary CLA^(9–11). Furthermore, little information is available about the effects of dietary CLA on non-specific immunity and antioxidant capacity in fish species⁽⁴⁾.

Previously, mechanisms related to the physiological effects of CLA have not been completely elucidated in any animal models. In mammals, dietary CLA can decrease oxidative stress and over-inflammation through suppressing the production of pro-inflammatory cytokines such as IL-2 and TNF- α as well as phospholipid-derived hormones, for example, eicosanoids^(16–19). CLA has also been found to exert physiological effects by modulating NF- κ B, which controls important cell signalling, phosphorylates certain transcription factors and subsequently activates relevant gene expression^(20–22). However, to our knowledge, no information is available about the effects of dietary CLA on the expression of genes related to inflammation and fatty acid oxidation under a formulation with constant *n*-3 highly unsaturated fatty acids (HUFA) and *n*-3:*n*-6 PUFA in any fish species. Cyclo-oxygenase-2 (COX-2) is a key biosynthetic enzyme in the synthesis of prostaglandins, such as PGE₂. It has been shown that COX-2 is dramatically up-regulated during pathological conditions, such as inflammation and cancer⁽²³⁾. Pro-inflammatory cytokines, IL-1 β and TNF- α , are key regulators of the immune system that shapes innate and adaptive immune responses⁽²⁴⁾. An adequate balance of the cytokine environment is critical to achieve protective immunity and to avoid immunopathology^(24–26).

PPAR α , carnitine palmitoyl transferase I (CPT1) and acyl CoA oxidase (ACO) participate in fatty acid oxidation and their expression levels could reflect the oxidative stress inside cells to some extent⁽²⁷⁾. Previous studies have investigated the relationship between the transcription of these genes and lipid metabolism^(1,28). It was shown that transcription of PPAR α could increase in the liver of the large yellow croaker as well as the muscle and adipose tissue of gilthead sea bream as dietary CLA increased from 0 to 4%^(1,28). However, little attention has been paid to the role of fatty acid oxidation-related genes in control of oxidative stress in fish species. Since inflammation, immune function and state of oxidative stress have been found to be closely correlated^(29,30), there is great interest to investigate the mRNA expression of fatty acid-related genes (PPAR α , CPT1 and ACO) in both the liver and kidney of large yellow croaker fed diets with graded levels of CLA.

The large yellow croaker (*Larimichthys crocea*) is an important marine fish species that is widely cultured in southeast China. During the past few years, studies on the nutrition of this fish have been conducted intensively^(31–35). However, as far we know, little information is available about the effects of fatty acid nutrition on immune function, antioxidant capacities and lipid deposition, especially mechanisms involved in these processes for this fish species. Thus, the pre-

sent study was conducted to investigate the effects of dietary CLA on growth performance, selected immunological parameters, antioxidant capacity and lipid deposition as well as on the expression of inflammation- and fatty acid oxidation-related genes in the large yellow croaker.

Materials and methods

Feed ingredients and diet formulation

Four isoproteic (42% crude protein) and isolipidic (12% crude lipid) diets were formulated to contain graded levels of CLA (0, 0.42, 0.83 and 1.70% dry diet) by adding different amounts of CLA-enriched oil (18:2 *cis*-9, *trans*-11: 38.86% total fatty acids (TFA); 18:2 *cis*-10, *trans*-12: 32.91% TFA; Aohai Biotechnology Co., Ltd). Then soyabean oil (China Oil and Foodstuffs Corp.) was added to a final amount of 7.0% oil mixture of dry diet. The optimal *n*-3 HUFA level (about 0.8% dry diet) was guaranteed by supplementing 30% white fishmeal (crude protein 74.3% DM, crude lipid 6.6% DM; Great Seven Biotechnology Co., Ltd) and 2.0% fish oil (arachidonic acid (ARA) content, 0.23% TFA; EPA content, 13.34% TFA; DHA content, 10.53% TFA; Great Seven Biotechnology Co., Ltd) in each diet according to the results of our previous study⁽³⁶⁾. White fishmeal and soyabean meal (crude protein 49.4% DM, crude lipid 0.9% DM; Great Seven Biotechnology Co., Ltd) were included as the main protein sources. Ingredients and nutrient composition of the four experimental diets are given in detail in Tables 1 and 2.

All ingredients were ground into fine powder so that they passed through a 246 μ m screen. Ingredients of each diet were blended thoroughly first by hand and then mechanically. The oil mixture was then thoroughly mixed with all ingredients of each diet, after which water (200 g/kg) was added to make stiff dough. Pellets (4 \times 5 mm and 5 \times 5 mm) were made using an automatic pellet-producing machine (Weihai) and dried for about 12 h in a ventilated oven at 40°C. After drying, feeds were packed in double plastic bags and stored at -20°C until used.

Fish rearing and sampling

Fish rearing and sampling were carried out according to the experimental procedures of the key laboratory of mariculture (Ministry of Education of China), Ocean University of China. Large yellow croaker were bought from a commercial farm in Xiangshan Bay, Ningbo, China. Before the start of the experiment, juveniles were reared in floating sea cages (3 \times 3 \times 3 m) and fed the control diet for 2 weeks to acclimatise to the experimental conditions and feeds.

At the start of the experiment, the fish were fasted for 24 h and weighed after being anaesthetised with eugenol (1:10 000) (Shanghai Reagent). Fish of similar sizes (7.56 (SEM 0.60) g) were distributed into twelve sea cages (1 \times 1 \times 1.5 m), and each cage was stocked with sixty fish. Each diet was randomly allocated to triplicate cages of fish. Fish were hand-fed twice daily (05.00 and 17.00 hours) to apparent satiation. The feeding trial lasted for 70 d. During

**Table 1.** Formulation and proximate analysis of the experimental diets (% dry weight)

	Dietary CLA level (%)			
	0	0.42	0.83	1.70
Ingredients				
White fishmeal*	30.00	30.00	30.00	30.00
Soyabean meal*	26.95	26.95	26.95	26.95
Wheat meal*	22.50	22.50	22.50	22.50
Casein*	5.00	5.00	5.00	5.00
Mineral premix†	2.00	2.00	2.00	2.00
Vitamin premix‡	2.00	2.00	2.00	2.00
Attractant§	0.40	0.40	0.40	0.40
Mold inhibitor	0.10	0.10	0.10	0.10
Yttrium oxide	0.05	0.05	0.05	0.05
Lecithin	2.00	2.00	2.00	2.00
Fish oil¶	2.00	2.00	2.00	2.00
CLA oil**	0	0.74	1.47	2.94
Soyabean oil††	7.00	6.26	5.53	4.06
Proximate analysis				
Crude protein	42.39	41.89	42.33	42.14
Crude lipid	14.31	13.86	14.19	14.20
CLA	0	0.42	0.83	1.70

CLA, conjugated linoleic acid; TFA, total fatty acids.

* White fishmeal: crude protein 74.3% DM, crude lipid 6.6% DM; soyabean meal: crude protein 49.4% DM, crude lipid 0.9% DM; wheat meal: crude protein 16.4% DM, crude lipid 1.0% DM (all supplied by Great Seven Biotechnology Co., Ltd). Casein: 93% crude protein and 1% crude lipid (Alfa Aesar, Avocado Research Chemicals Ltd).

† Mineral premix (mg or g/kg diet): CuSO₄·5H₂O, 10 mg; Na₂SeO₃ (1%), 25 mg; ZnSO₄·H₂O, 50 mg; CoCl₂·6H₂O (1%), 50 mg; MnSO₄·H₂O, 60 mg; FeSO₄·H₂O, 80 mg; Ca(IO₃)₂, 180 mg; MgSO₄·7H₂O, 1200 mg; zeolite, 18.35 g.

‡ Vitamin premix (mg or g/kg diet): vitamin D, 5 mg; vitamin K, 10 mg; vitamin B₁₂, 10 mg; vitamin B₆, 20 mg; folic acid, 20 mg; vitamin B₁, 25 mg; vitamin A, 32 mg; vitamin B₂, 45 mg; pantothenic acid, 60 mg; biotin, 60 mg; niacin acid, 200 mg; α-tocopherol, 240 mg; inositol, 800 mg; ascorbic acid, 2000 mg; microcrystalline cellulose, 16.47 g.

§ Attractant: glycine and betaine.

|| Mold inhibitor: contained 50% calcium propionic acid and 50% fumaric acid.

¶ Fish oil: palmitic acid (16:0) content, 15.77% TFA; oleic acid (18:1n-9) content, 3.29% TFA; linoleic acid (18:2n-6) content, 2.12% TFA; linolenic acid (18:3n-3) content, 0.42% TFA; arachidonic acid content, 0.23% TFA; EPA content, 13.34% TFA; DHA content, 10.53% TFA (Great Seven Biotechnology Co., Ltd).

** CLA oil: palmitic acid (16:0) content, 3.17% TFA; oleic acid (18:1n-9) content, 14.34% TFA; linoleic acid (18:2n-6) content, 2.24% TFA; 18:2 *cis*-9, *trans*-11 content, 38.86% TFA; 18:2 *cis*-10, *trans*-12 content, 32.91% TFA (Aohai Biotechnology Co., Ltd).

†† Soyabean oil: palmitic acid (16:0) content, 10.90% TFA; oleic acid (18:1n-9) content, 16.18% TFA; linoleic acid (18:2n-6) content, 51.22% TFA; linolenic acid (18:3n-3) content, 6.12% TFA (China Oil and Foodstuffs Corp.).

the experimental period, water temperature, salinity and dissolved O₂ were measured daily. The water temperature ranged from 24 to 30°C, and salinity from 32 to 36‰. The dissolved O₂ was approximately 7 mg/l.

At the termination of the experiment, fish were fasted for 24 h before harvest. Then, experimental fish in each cage were weighed one by one and final fish number was recorded after they were anaesthetised with eugenol as described above. After that, blood samples were obtained from the caudal vein of five fish from each cage with 27-gauge needles and 1 ml syringes and allowed to clot at room temperature for 4 h and then at 4°C for a further 6 h. The clot was removed and residual blood cells were separated from the straw-coloured serum by centrifugation (836 g; 10 min; 4°C). The serum was frozen in liquid N₂ and then stored at -80°C for later analysis of lysozyme activity. Livers and kidneys from five fish in each cage were pooled into 1.5 ml tubes (RNAase-Free; Axygen), frozen in liquid N₂ and then stored at -80°C for later analysis

of gene expression related to inflammation and fatty acid oxidation. Liver and muscle from another ten fish in each cage were pooled into 10 ml tubes, frozen in liquid N₂ and then stored at -80°C for the assay of fatty acid composition, moisture and crude lipids. Whole bodies of six fish in each cage were collected into plastic bags and then stored at -20°C for the assay of moisture and crude lipids.

Biochemical analysis

Crude protein was determined by digestion using the Kjeldahl method (Kjeltec FOSS 2300; Tecator) and estimated by multiplying N by 6.25. Crude lipid was measured by ether extraction using the Soxhlet method (Soxhlet Extraction System B-811). Fatty acid profiles were analysed using the procedures described by Metcalfe *et al.*⁽³⁷⁾ with some modification⁽³³⁾. About 100 mg freeze-dried samples/50 µl oil were added into a 20 ml volumetric screwed tube with a cover. Then 3 ml potassium hydroxide methanol (1 M) were added and heated in a 72°C water-bath for 20 min. After that, 3 ml hydrogen chloride methanol (2 M) were added and the mixture was heated in a 72°C water-bath for another 20 min. Previous tests were conducted to make sure that all fatty acids could be esterified following the procedures above. Finally, 1 ml hexane was added into the mixture above, shaken vigorously for 1 min, and then allowed to separate into two layers. Fatty acid methyl esters were separated, and quantified by a HP6890 gas chromatograph (Agilent Technologies Inc.) with a fused silica capillary column (007-CW; Hewlett Packard) and a flame ionisation detector. The column temperature was

Table 2. Fatty acid composition (% total fatty acids) of the experimental diets with different levels of conjugated linoleic acid (CLA)*

Fatty acid	Dietary CLA level (%)			
	0	0.42	0.83	1.70
14:0	2.11	2.06	2.11	1.96
16:0	16.05	15.56	15.25	14.23
18:0	4.26	4.25	4.08	3.92
20:0	0.41	0.42	0.40	0.42
ΣSFA	22.83	22.37	21.84	20.53
16:1	2.83	2.78	2.89	2.91
18:1	22.39	21.63	21.71	20.74
ΣMUFA	25.22	24.42	24.59	23.65
18:2n-6	37.53	35.07	33.60	27.83
18:2 <i>cis</i> -9, <i>trans</i> -11	0.00	1.01	2.49	5.07
18:2 <i>trans</i> -10, <i>cis</i> -12	0.00	2.55	4.36	8.82
20:4n-6 (ARA)	1.78	1.88	1.87	1.79
Σn-6 PUFA	39.31	40.52	42.33	43.51
18:3n-3	4.43	3.88	3.70	3.06
20:5n-3 (EPA)	3.87	3.81	3.92	3.99
22:6n-3 (DHA)	3.74	3.67	3.71	3.91
Σn-3 PUFA	12.03	11.36	11.33	10.97
n-3:n-6 PUFA	0.30	0.28	0.27	0.25
n-3 HUFA	7.61	7.48	7.63	7.91
ARA:EPA	0.43	0.49	0.48	0.45
DHA:EPA	0.96	0.96	0.95	0.98
CLA	0.00	3.57	6.86	13.89

ARA, arachidonic acid; HUFA, highly unsaturated fatty acids (EPA + DHA).

* Some fatty acids, of which the contents are minor, in trace amounts or not detected (such as 22:0, 24:0, 14:1, 20:1n-9, 22:1n-11, 20:2n-6, 20:3n-6 and 22:5n-3), are not listed in the Table.

programmed to rise from 150°C up to 200°C at a rate of 15°C/min, and from 200°C to 250°C at a rate of 2°C/min. Injector and detector temperatures were both 250°C.

Functional immune assays

Phagocytic index. Phagocytic index (PI) was measured according to the method of Pulsford *et al.*⁽³⁸⁾ with some modification. Head kidneys of six fish per cage were removed, homogenised in the modified formula of L-15 culture medium (10 µg/ml heparin; 200 U/ml penicillin/streptomycin; 15 mM-HEPES; 1% fetal bovine serum) and then filtered through a 100 µm nylon mesh. The resulting cell suspensions were enriched by centrifugation (836 g, 25 min, 4°C) on a 34%/51% Percoll (Pharmacia) density gradient. The cells were collected at the 34–51% interface and washed twice using L-15 culture medium above. Then 100 µl cell suspensions were stained with 100 µl trypan blue (0.4%; Sigma) at 23.5°C for 1 min, and then detected under a microscope (40×) to determine the cell concentration and viability. The cell viability was more than 95% and final cell concentration was adjusted to approximately 1×10^7 leucocytes/ml. Then 100 µl cell suspensions of head kidney leucocytes and 100 µl yeast suspension (Bakers yeast, Type II, Sigma; 1×10^8 cells/ml) were mixed into a 2 ml-sized plastic tube and cultured at 23.5°C for 40 min. To calculate the PI, a sample of mixture was put into the blood cell counting plate (Shanghai Qiuqing Biochemical Reagent and Apparatus Co., Ltd) and 200 cells were counted where the number of cells with ingested yeasts was recorded.

Respiratory burst activity. Production of intracellular superoxide anion ($O_2^{\cdot-}$) for five fish from each cage was evaluated using nitroblue tetrazolium (NBT) (Sigma) reduction following the method of Secombes⁽³⁹⁾ with some modifications. A 100 µl cell suspension was stained with 100 µl NBT (1 mg/ml) and 100 µl phorbol 12-myristate 13-acetate (PMA; 1 µg/ml; Sigma) which was used as a trigger for $O_2^{\cdot-}$ production for 45 min. Absolute methanol was added to terminate the staining. Each tube was washed three times with 70% methanol and air-dried. Then, 120 µl 2 M-KOH and 140 µl dimethyl sulfoxide (DMSO) were added and absorbance was measured at 630 nm with a spectrophotometer using KOH/DMSO as a blank.

Lysozyme activity. Lysozyme activity in serum was measured according to the method of Ellis⁽⁴⁰⁾. Briefly, a sample of 0.05 ml serum was added to 1.4 ml of a suspension of *Micrococcus lysodeikticus* (Sigma) (0.2 mg/ml) in a 0.1 M-sodium phosphate buffer (pH 6.8). The reaction was carried out at 25°C and absorbance was measured at 530 nm after 0.5 and 4.5 min in a spectrophotometer. Each unit is defined as the amount of sample causing a decrease in absorbance of 0.001/min.

Hepatic antioxidative capacity assays. Liver samples were first ground into powder in liquid N_2 and then homogenised in nine volumes of ice-cold phosphate solution (pH 7.4) and centrifuged at 4000 g for 10 min at 4°C. After that, the supernatant fraction was determined for soluble protein by the method of Bradford⁽⁴¹⁾ using bovine serum albumin as standard and then stored at –80°C until use.

Total antioxidative capacity. Total antioxidative capacity was assayed using a commercial kit (Nanjing Jiancheng Bio-engineering Institute). Briefly, Fe^{3+} can be reduced to Fe^{2+} under some antioxidative enzyme systems and Fe^{2+} can combine with phenanthroline. Absorbance was read at 520 nm, with distilled water as blanks. Results are expressed in units of total antioxidative capacity per mg soluble protein and each unit is defined as the amount of enzyme that can increase the absorbance by 0.01 in 1 min at 37°C.

Catalase activity. Hepatic catalase (CAT) was assayed using a commercial kit (Nanjing Jiancheng Bio-engineering Institute). CAT reacts with H_2O_2 for exactly 1 min and then ammonium molybdate was quickly added to stop the reaction⁽⁴²⁾. The remaining H_2O_2 can react with ammonium molybdate and generate a light-yellow complex. The CAT activity can be calculated by assaying the absorbance at 405 nm, with distilled water as blanks. Results are expressed in units of CAT per mg soluble protein and each unit is defined as the amount of enzyme necessary to resolve 1 µmol H_2O_2 in 1 s at 37°C.

Superoxide dismutase activity. Superoxide dismutase activity was measured spectrophotometrically by the ferricytochrome *c* method using xanthine/xanthine oxidase as the source of superoxide radicals. The reaction mixture consisted of 50 mM-potassium phosphate buffer (pH 7.8), 0.1 mM-EDTA, 0.1 mM-xanthine, 0.013 mM-cytochrome *c* and xanthine oxidase (0.024 IU/ml). The reaction was triggered by the addition of the xanthine oxidase. Results are expressed in units of superoxide dismutase per mg soluble protein and each unit is defined as the amount of enzyme necessary to produce 50% inhibition of the ferricytochrome *c* reduction rate measured at 550 nm⁽⁴³⁾.

Malondialdehyde content. Malondialdehyde (MDA) as one of the metabolites derived from lipid peroxidation was measured using the thiobarbituric acid (TBA) assay kit (Nanjing Jiancheng Bio-Engineering Institute). MDA reacts with TBA to produce a pink-coloured material that can readily be monitored by a spectrophotometer to give an overall indication of the level of lipid peroxidation⁽⁴⁴⁾. Generally speaking, 100 µl supernatant fraction of liver homogenates in each replicate were incubated with 20% TCA and 0.67% TBA at 95°C for 40 min. Absorbance was read at 532 nm, with distilled water as blanks. Results were converted to nmol MDA per mg soluble protein using a standard sample of 10 nmol/ml malonaldehyde diethyl acetate.

RNA extraction and real-time quantitative PCR

Total RNA was extracted from the liver and kidneys using Trizol Reagent (Invitrogen) and electrophoresed on a 1.2% denaturing agarose gel to test the integrity. The RNA was treated with RNA-Free DNase (Takara) to remove DNA and reverse transcribed to complementary DNA (cDNA) by a PrimeScript™ RT Reagent Kit (Takara) following the instructions. First-strand cDNA was diluted by four times using sterilised double-distilled water. Real-time quantitative PCR was carried out in a quantitative thermal cycler (Mastercycler® ep realplex; Eppendorf). The amplification was performed in a total volume of 25 µl, containing 1 µl of each primer (10 µM), 1 µl of the diluted first-strand cDNA product, 12.5 µl of

Table 3. Real-time quantitative PCR primers for inflammation- and fatty acid oxidation-related genes and β -actin of the large yellow croaker (*Larimichthys crocea*)

Gene	Nucleotide sequence (5'–3')	Size (bp)	GenBank reference or publication
<i>COX-2</i>	F: ACCATCTGGCTGCGGGAAC R: GAATGAGTCGTGTGGTCTGGAAG	100	JX520677
<i>IL-1β</i>	F: AGCCAATCTGGCAAGGATCA R: GCTGATGAACCAGTTGTTGT	121	DQ306711
<i>TNF-α</i>	F: CGTCCTGGTGTTCGTTGGT R: TGTTTTCTCGGCAGTCGTCTT	100	Xie <i>et al.</i> ⁽⁴⁵⁾
<i>PPARα</i>	F: GTCAAGCAGATCCACGAAGCC R: TGGTCTTTCCAGTGAGTATGAGCC	82	Zhao <i>et al.</i> ⁽²⁸⁾
<i>CPT1</i>	F: GCTGAGCCTGGTGAAGATGTTC R: TCCATTTGGTTGAATTGTTACTGTCC	159	JX434612
<i>ACO</i>	F: TTCTCAACGACCCAGACTTTAAGG R: GTTGCTCTGACCATATTCTTATAGC	167	JX456348
β -Actin	F: TTATGAAGGCTATGCCTGCC R: TGAAGGAGTAGCCACGCTCTGT	107	Yao <i>et al.</i> ⁽⁴⁶⁾

COX-2, cyclo-oxygenase-2; F, forward; R, reverse; *CPT1*, carnitine palmitoyl transferase I; *ACO*, acyl CoA oxidase.

2 \times SYBR[®] Premix Ex Taq[™] II (Takara) and 9.5 μ l of sterilised double-distilled water. The real-time PCR programme was as follows: 95°C for 2 min, followed by forty cycles of 95°C for 10 s, 58°C for 10 s, and 72°C for 20 s. The primer sequence for β -actin, *COX-2*, *IL-1 β* , *TNF- α* , *PPAR α* , *CPT1* and *ACO* were designed following the published sequences for the large yellow croaker from GenBank or published papers^(28,45,46) and listed in Table 3. PCR fragments amplified by each pair of primers were sequenced, blasted and analysed to assure the specificity of each primer pair. At the end of each PCR reaction, melting curve analysis was performed to confirm that only one PCR product was present in these reactions. Standard curves were made with five different dilutions (in triplicate) of the cDNA samples and amplification efficiency was analysed according to the following equation $E = 10^{(-1/\text{slope})} - 1$. The primer amplification efficiency was 1.020 for β -actin, 1.004 for *COX-2*, 0.9954 for *IL-1 β* , 1.0188 for *TNF- α* , 0.9924 for *PPAR α* , 1.1190 for *CPT1* and 1.0813 for *ACO*. The absolute ΔC_T (cycle threshold) values between the target gene and inner control gene were all close to zero and indicate that the $\Delta\Delta C_T$ calculation for the relative quantification of target genes can be used. To calculate gene expression, the comparative CT method ($2^{-\Delta\Delta C_T}$ method) was used as described by Yao *et al.*⁽⁴⁶⁾.

Calculations and statistical analysis

Growth parameters were calculated as follows:

Survival rate (%) = 100 \times (final fish number/initial fish number).

Feed intake (g/kg average body weight per d)
= feed consumed (g)/((IBW + FBW)/2/1000 (kg))/d.

Weight gain rate (%) = 100 \times ((final body weight
– initial body weight)/
initial body weight).

Feed efficiency ratio = wet weight gain (g)/
dry feed consumed (g).

Viserosomatic index (%) = 100 \times (visceral weight/body weight).

Hepatosomatic index (%) = 100 \times (liver weight/body weight).

PI (%) = leucocytes with ingested yeast/
200 observed leucocytes under the microscope.

Statistical analysis was performed by using SPSS 16.0 for Windows (SPSS Inc.). All data were subjected to a one-way ANOVA and differences between the means were tested by Tukey's multiple-range test. The level of significance was set at $P < 0.05$ and the results are presented as mean values with their standard errors.

Results

Survival rate, growth performance and somatic indices

Survival rate of large yellow croaker for all dietary treatments was above 91.0% and there were no significant differences among dietary treatments in the present study ($P > 0.05$). No statistical differences were detected in feed intake among dietary treatments (19.11–20.74 g/kg average body weight per d) ($P > 0.05$). As dietary CLA increased from 0 to 0.42%, weight gain rate increased significantly from 499.30 to 572.52% ($P < 0.01$), and then decreased to 444.21% with dietary CLA increasing from 0.42 to 1.70% ($P < 0.05$). No significance was detected in the feed efficiency ratio of experimental fish among dietary treatments ($P > 0.05$). The viserosomatic index of fish fed the 0.42% CLA diet (6.79%) was significantly higher than that of fish in the control (6.06%) and 1.70% CLA treatment (6.27%) groups ($P < 0.05$). Hepatosomatic index significantly increased from 1.40 to 1.93% with the increase of dietary CLA ($P < 0.05$) (Table 4).

Immunological and hepatic antioxidative parameters

As dietary CLA increased from 0 to 0.42%, PI increased significantly from 17.9 to 34.7%, and then decreased to 24.7% with dietary CLA increasing from 0.42 to 1.70% ($P < 0.05$). Respiratory burst activity (value of optical density (OD) 630) showed a similar trend to PI as dietary CLA increased. Respiratory

Table 4. Effects of dietary conjugated linoleic acid (CLA) on growth, survival and selected body parameters of large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets

(Mean values with their standard errors for three determinations)

	Dietary CLA level (%)								ANOVA <i>P</i>
	0		0.42		0.83		1.70		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
IBW (g)	7.56	0.60	7.56	0.60	7.56	0.60	7.56	0.60	
FBW (g)	45.31 ^{a,b}	1.39	50.84 ^c	1.25	47.45 ^{b,c}	0.08	41.14 ^a	0.68	0.002
WGR (%)*	499.30 ^{a,b}	18.42	572.52 ^c	16.47	527.69 ^{b,c}	1.03	444.21 ^a	9.05	0.002
SR (%)†	91.78	1.11	92.22	3.64	96.89	0.56	95.44	2.94	0.133
FI (g/kg average body weight per d)‡	19.63	0.54	20.74	0.83	19.50	1.22	19.11	1.52	0.066
FER§	0.95	0.03	1.03	0.05	1.06	0.10	1.03	0.04	0.282
VSI	6.06 ^a	0.10	6.79 ^b	0.09	6.45 ^{a,b}	0.11	6.27 ^a	0.00	0.014
HSI¶	1.40 ^a	0.06	1.74 ^b	0.03	1.76 ^b	0.05	1.93 ^b	0.09	0.002

IBW, initial mean body weight; FBW, final mean body weight; WGR, weight gain rate; SR, survival rate; FI, feed intake; FER, feed efficiency ratio; VSI, viserosomatic index; HSI, hepatosomatic index.

^{a,b,c} Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$).

* WGR (%) = $100 \times ((\text{FBW} - \text{IBW})/\text{IBW})$.

† SR (%) = $100 \times \text{final fish number}/\text{initial fish number}$.

‡ FI (g/kg average body weight per d) = $\text{feed consumed (g)} / ((\text{IBW} + \text{FBW})/2/1000 \text{ (kg)})/\text{d}$.

§ FER = $\text{wet weight gain (g)}/\text{dry feed consumed (g)}$.

|| VSI (%) = $100 \times (\text{visceral weight}/\text{body weight})$.

¶ HSI (%) = $100 \times (\text{liver weight}/\text{body weight})$.

burst activity was significantly increased by 0.83% CLA (OD630 = 0.50) compared with the control (OD630 = 0.34) and 1.70% CLA treatment (OD630 = 0.42) groups ($P < 0.05$). However, no significant differences were observed in this parameter between the control and the 1.70% CLA groups ($P > 0.05$). There were no statistical differences in serum lysozyme activity among four dietary treatments ($P > 0.05$) (Table 5).

Total antioxidative capacity increased significantly from 0.29 to 2.14 units/mg protein as dietary CLA increased from 0 to 0.83%, and then decreased significantly to 1.22 units/mg protein with further increase of CLA ($P < 0.05$). Hepatic CAT increased significantly from 36.46 to 71.45 units/mg protein as dietary CLA increased from 0 to 0.83%, and then decreased significantly to 32.58 units/mg protein with further increase of CLA ($P < 0.05$). Superoxide dismutase activity in the liver increased from 21.68 to 29.64 units/mg protein as dietary CLA increased from 0 to 0.42% and then decreased to 18.95

units/mg protein with further increase of this fatty acid ($P > 0.05$). MDA content in the liver decreased significantly from 3.30 to 1.66 nmol/mg protein with the increase of dietary CLA ($P < 0.05$) (Table 5).

Proximate composition of whole body, muscle and liver

No significant difference was detected in moisture content of the whole body, liver and muscle ($P > 0.05$). The lipid content of the whole body and muscle increased significantly with the increase of dietary CLA ($P < 0.05$). The whole body lipid content of fish fed the diets with 1.70% CLA (8.51% wet weight) was significantly higher compared with the control (7.44% wet weight) and 0.42% CLA treatment (7.38% wet weight) groups ($P < 0.05$). The muscle lipid content of fish fed the diets with 0.83% CLA (7.26% wet weight) was significantly higher compared with the control (5.97% wet weight)

Table 5. Effects of dietary conjugated linoleic acid (CLA) on selected immunological and hepatic antioxidative parameters of large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets

(Mean values with their standard errors for three determinations)

	Dietary CLA level (%)								ANOVA <i>P</i>
	0		0.42		0.83		1.70		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
PI (%)*	17.9 ^a	0.5	34.7 ^b	1.7	33.7 ^{b,c}	2.4	24.7 ^{a,c}	2.0	0.002
OD630†	0.34 ^a	0.02	0.44 ^{b,c}	0.01	0.50 ^c	0.02	0.42 ^{a,b}	0.01	0.001
Lysozyme activity (units/ml)	137.00	9.61	93.50	4.50	92.50	1.50	113.50	5.50	0.550
T-AOC (units/mg protein)	0.29 ^a	0.06	1.69 ^b	0.34	2.14 ^b	0.18	1.22 ^c	0.36	0.018
CAT (units/mg protein)	36.46 ^a	5.52	45.94 ^{a,b}	2.73	71.45 ^b	7.56	32.58 ^a	9.58	0.034
SOD (units/mg protein)	21.68	2.72	29.24	4.06	25.66	0.95	18.95	2.09	0.162
MDA (nmol/mg protein)	3.30 ^a	0.44	2.80 ^{ab}	0.24	1.61 ^b	0.16	1.66 ^b	0.18	0.006

PI, phagocytic index; OD, optical density; T-AOC, total antioxidative capacity; CAT, catalase; SOD, superoxide dismutase; MDA, malondialdehyde.

^{a,b,c} Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$).

* PI (%) = $\text{leucocytes with ingested yeast}/200 \text{ observed leucocytes under the microscope}$.

† OD630, respiratory burst of activity.

Table 6. Effect of dietary conjugated linoleic acid (CLA) on composition of the whole body, liver and muscle (% of live weight) of juvenile large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets (Mean values with their standard errors for three determinations)

	Dietary CLA level (%)								ANOVA <i>P</i>
	0		0.42		0.83		1.70		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
Whole body									
Moisture	73.77	0.66	72.70	1.32	74.67	0.22	73.55	0.53	0.423
Lipid	7.44 ^a	0.19	7.38 ^a	0.58	8.25 ^b	0.32	8.51 ^b	0.30	0.011
Liver									
Moisture	64.29	1.27	61.96	1.10	64.34	1.41	62.42	0.48	0.404
Lipid	19.31	2.33	19.53	1.66	18.80	1.56	19.09	0.38	0.994
Muscle									
Moisture	75.54	1.44	76.50	0.57	75.82	1.17	74.73	0.64	0.761
Lipid	5.97 ^a	0.04	5.47 ^a	0.11	7.26 ^b	0.01	6.49 ^{a,b}	0.10	0.035

^{a,b} Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$).

and 0.42% CLA treatment (5.47% wet weight) groups ($P < 0.05$). There were no significant differences in liver lipid concentration among dietary treatments ($P > 0.05$) (Table 6).

Liver and muscle fatty acid profiles

Deposition of CLA isomers, 18:2 *cis*-9, *trans*-11 and 18:2 *trans*-10, *cis*-12, were increased with the increase of dietary CLA ($P < 0.05$). Dietary CLA modified significantly the retention of SFA, MUFA and ARA in the liver. The total percentage

of SFA, mainly 14:0, 16:0 and 18:0, increased with dietary CLA increasing to 0.42%, and then decreased with further increase of CLA. The hepatic concentration of 16:0 in the 0.83% CLA treatment group (18.97% TFA) was significantly higher than that in the control (16.78% TFA) and 1.70% CLA treatment (16.43% TFA) groups ($P < 0.05$). Hepatic 18:0 content in the 0.42% CLA treatment group (10.64% TFA) was significantly higher than that in the control group (4.92% TFA) ($P < 0.05$). MUFA percentage in the liver decreased by a reduction in 16:1 *n*-9 and 18:1 *n*-9 as dietary CLA increased

Table 7. Fatty acid composition (% total fatty acids) in the liver of juvenile large yellow croaker (*Larimichthys crocea*) fed diets with graded levels of conjugated linoleic acid (CLA)*

(Mean values with their standard errors for three determinations)

Fatty acid	Dietary CLA level (%)								ANOVA <i>P</i>
	0		0.42		0.83		1.70		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
14:0	1.48	0.01	1.64	0.02	1.81	0.15	1.67	0.08	0.213
16:0	16.78 ^a	0.35	18.01 ^{a,b}	0.27	18.97 ^b	0.76	16.43 ^a	0.40	0.020
18:0	4.92 ^a	0.58	10.64 ^b	1.44	7.60 ^{a,b}	1.33	7.11 ^{a,b}	1.15	0.047
20:0	0.27 ^a	0.04	0.18 ^{a,b}	0.01	0.18 ^{a,b}	0.05	0.48 ^c	0.04	0.023
ΣSFA	23.59 ^a	0.94	31.36 ^b	1.54	29.84 ^b	2.06	25.69 ^{a,b}	1.47	0.041
16:1	6.93 ^a	0.13	4.08 ^b	0.07	4.00 ^b	0.32	3.90 ^b	0.08	0.000
18:1	24.88 ^a	1.17	18.65 ^b	0.57	21.38 ^{a,b}	1.77	19.68 ^b	0.17	0.012
ΣMUFA	31.26 ^a	1.72	22.74 ^b	0.64	25.62 ^b	0.01	23.60 ^b	0.24	0.002
18:2 <i>n</i> -6	32.29 ^a	0.72	31.30 ^a	0.68	27.01 ^{a,b}	2.96	25.97 ^b	1.06	0.046
18:2 <i>cis</i> -9, <i>trans</i> -11	0.00 ^a	0.00	1.01 ^b	0.03	1.54 ^b	0.16	4.52 ^c	0.34	0.000
18:2 <i>trans</i> -10, <i>cis</i> -12	0.00 ^a	0.00	1.28 ^b	0.02	1.99 ^b	0.22	5.60 ^c	0.43	0.000
20:4 <i>n</i> -6 (ARA)	1.64 ^a	0.06	1.75 ^{a,b}	0.03	2.16 ^b	0.11	2.72 ^c	0.15	0.000
Σ <i>n</i> -6 PUFA	33.93 ^a	0.74	34.64 ^a	0.75	33.24 ^a	1.39	38.91 ^b	1.89	0.039
18:3 <i>n</i> -3	3.47	0.43	3.26	0.13	2.59	0.19	2.61	0.08	0.122
20:5 <i>n</i> -3 (EPA)	1.51	0.15	1.45	0.09	1.44	0.12	1.68	0.15	0.559
22:6 <i>n</i> -3 (DHA)	1.60	0.13	1.55	0.13	1.45	0.14	1.78	0.22	0.543
Σ <i>n</i> -3 PUFA	6.59	0.70	6.25	0.34	5.48	0.27	6.54	0.39	0.349
<i>n</i> -3: <i>n</i> -6 PUFA	0.19	0.02	0.17	0.01	0.15	0.01	0.17	0.02	0.631
<i>n</i> -3 HUFA	3.11	0.28	2.99	0.21	2.89	0.18	3.10	0.00	0.875
ARA:EPA	1.11 ^a	0.12	1.22 ^{a,b}	0.06	1.67 ^{b,c}	0.05	1.79 ^c	0.11	0.006
DHA:EPA	1.06	0.04	1.07	0.03	1.02	0.12	1.05	0.05	0.972
CLA	0.00 ^a	0.00	2.29 ^b	0.05	3.54 ^b	0.37	10.11 ^c	0.77	0.000

ARA, arachidonic acid; HUFA, highly unsaturated fatty acids (EPA + DHA).

^{a,b,c} Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$).

* Some fatty acids, of which the contents are minor, in trace amounts or not detected (such as 22:0, 24:0, 14:1, 20:1 *n*-9, 22:1 *n*-11, 20:2 *n*-6, 20:3 *n*-6 and 22:5 *n*-3), are not listed in the Table.

Table 8. Fatty acid composition (% total fatty acids) in the muscle of juvenile large yellow croaker (*Larimichthys crocea*) fed diets with graded levels of conjugated linoleic acid (CLA)*

(Mean values with their standard errors for three determinations)

Fatty acid	Dietary CLA level (%)								ANOVA P
	0		0.42		0.83		1.70		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
14:0	1.77	0.13	1.75	0.12	1.73	0.10	1.82	0.04	0.932
16:0	16.77	0.57	17.29	0.20	16.96	0.06	16.11	0.16	0.132
18:0	4.64 ^a	0.10	6.40 ^{a,b}	0.23	8.01 ^b	0.60	6.70 ^{a,b}	0.28	0.002
20:0	0.27 ^a	0.01	0.15 ^a	0.02	0.17 ^a	0.03	0.56 ^b	0.08	0.001
ΣSFA	23.45	0.60	25.84	2.24	26.87	0.53	25.19	0.10	0.121
16:1	3.84 ^a	0.16	3.33 ^b	0.07	3.11 ^b	0.11	2.95 ^b	0.05	0.002
18:1	22.19 ^a	0.46	19.84 ^{a,b}	1.04	20.27 ^{a,b}	0.11	19.11 ^b	0.06	0.027
ΣMUFA	26.03 ^a	0.60	23.18 ^b	1.03	23.39 ^{a,b}	0.14	22.05 ^b	0.10	0.009
18:2n-6	32.89 ^a	0.74	28.95 ^b	1.45	27.07 ^{b,c}	0.15	24.31 ^c	0.29	0.001
18:2 cis-9, trans-11	0.00 ^a	0.00	1.11 ^b	0.03	2.29 ^c	0.05	4.78 ^d	0.05	0.000
18:2 trans-10, cis-12	0.00 ^a	0.00	1.65 ^b	0.10	3.26 ^c	0.01	6.81 ^d	0.02	0.000
20:4n-6 (ARA)	1.93 ^{a,b}	0.07	1.88 ^a	0.03	2.34 ^{b,c}	0.17	2.61 ^c	0.01	0.002
Σn-6 PUFA	34.82 ^a	0.77	33.37 ^a	1.46	35.51 ^{a,b}	0.05	40.10 ^b	0.29	0.016
18:3n-3	3.67 ^a	0.08	3.29 ^{a,b}	0.13	3.14 ^{b,c}	0.02	2.86 ^c	0.05	0.001
20:5n-3 (EPA)	2.98	0.12	2.99	0.07	2.99	0.00	2.99	0.05	1.000
22:6n-3 (DHA)	4.01	0.28	3.74	0.32	3.85	0.22	3.78	0.07	0.869
Σn-3 PUFA	10.67	0.47	10.03	0.42	9.99	0.23	9.63	0.17	0.273
n-3:n-6 PUFA	0.31 ^a	0.01	0.29 ^{a,b}	0.01	0.28 ^{a,b}	0.01	0.25 ^b	0.01	0.022
n-3 HUFA	6.99	0.39	6.73	0.35	6.84	0.22	6.77	0.12	0.921
ARA:EPA	0.65 ^a	0.03	0.63 ^a	0.02	0.78 ^{a,b}	0.06	0.87 ^b	0.03	0.004
DHA:EPA	1.34	0.06	1.25	0.10	1.29	0.07	1.27	0.01	0.803
CLA	0.00 ^a	0.00	2.77 ^b	0.12	5.55 ^c	0.06	11.59 ^d	0.06	0.000

ARA, arachidonic acid; HUFA, highly unsaturated fatty acids (EPA + DHA).

^{a,b,c,d} Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$).

* Some fatty acids, of which the contents are minor, in trace amounts or not detected (such as 22:0, 24:0, 14:1, 20:1n-9, 22:1n-11, 20:2n-6, 20:3n-6 and 22:5n-3), are not listed in the Table.

($P < 0.05$). The percentage of ARA increased significantly from 1.64 to 2.72% TFA as dietary CLA increased. The ARA:EPA ratio increased significantly from 1.11 to 2.79 with the increase in dietary CLA. There were no significant differences in the content of n-3 HUFA or the ratio of DHA:EPA among dietary treatments ($P > 0.05$) (Table 7).

For muscle, the concentration of biologically active isomers, 18:2 cis-9, trans-11 and 18:2 trans-10, cis-12, increased significantly with increasing dietary inclusion of CLA ($P < 0.05$). The content of SFA in muscle increased, while MUFA decreased as dietary CLA increased ($P < 0.05$). The 18:0 content of muscle in the 0.83% CLA treatment group (8.01% TFA) was comparable with that in the 0.42% CLA (6.40% TFA) and 1.70% CLA (6.70% TFA) treatment groups, but significantly higher than that in the control treatment group (4.64% TFA) ($P < 0.05$). ARA increased significantly from 1.93 to 2.61% TFA as dietary CLA increased. The ARA:EPA ratio increased significantly from 0.65 to 0.87 with the increase in dietary CLA. No significant differences were detected in the concentration of n-3 HUFA or the DHA:EPA ratio among dietary treatments ($P > 0.05$) (Table 8).

Expression of inflammation- and fatty acid oxidation-related genes

The transcriptional levels of *COX-2* and *IL-1β* in the liver and kidney decreased significantly with increasing dietary CLA. Hepatic *COX-2* mRNA expression level was significantly

decreased by approximately 0.30-fold, 0.67-fold and 0.72-fold in the 0.42, 0.83 and 1.70% CLA treatment groups, respectively ($P < 0.05$) (Fig. 1(A)). The kidney *COX-2* mRNA transcriptional level was significantly decreased by about 0.60-fold, 0.70-fold and 0.85-fold in the 0.42, 0.83 and 1.70% CLA treatment groups than that in the control group, respectively ($P < 0.05$) (Fig. 1(B)). *IL-1β* mRNA levels of fish fed diets with 0.83 and 1.70% CLA were significantly decreased by about 0.90-fold in the liver and 0.60-fold in the kidney compared with the control group, respectively ($P < 0.05$) (Fig. 1(A) and (B)). There were no significant differences in the transcription of *TNF-α* in the liver and kidney among dietary treatments ($P > 0.05$) (Fig. 1(A) and (B)).

Hepatic *PPARα* transcriptional levels increased significantly to the maximum levels with dietary CLA increasing from 0 to 0.42%, and thereafter decreased significantly with further increase of dietary CLA ($P < 0.05$). mRNA expression levels of *PPARα* were increased by 0.89-fold in the 0.42% CLA treatment group while they decreased by 0.1-fold and 0.4-fold in the 0.73 and 1.70% dietary CLA treatment groups compared with the control treatment. The hepatic transcriptional levels of *CPT1* in the 0.83 and 1.70% CLA treatment groups were about 1.40-fold higher than those of the control and 0.42% CLA treatment groups. The *ACO* transcriptional levels in the liver of fish fed diets with equal to or above 0.42% CLA were decreased by more than 0.50-fold compared with the control group (Fig. 2(A)).




Fig. 1. Effects of dietary conjugated linoleic acid (CLA) on relative mRNA expression of inflammation-related genes (cyclo-oxygenase-2 (*COX-2*; ■), *IL-1β* (▨) and *TNF-α* (▩)) in the liver (A) and kidneys (B) of juvenile large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets. Values are means (*n* 3), with their standard errors represented by vertical bars. ^{a,b} Mean values for the same gene with unlike letters were significantly different (*P* < 0.05; Tukey's test).

There was no significant difference in kidney *PPARα* mRNA expression among dietary treatments, though a decreasing trend was observed as dietary CLA increased (*P* > 0.05). The transcription levels of *CPT1* and *ACO* in the kidney decreased significantly as dietary CLA increased. *CPT1* transcriptional levels in the kidney of fish fed diets with equal to or above 0.42% CLA were significantly decreased by about 0.50-fold compared with the control treatment group (*P* < 0.05). *ACO* transcriptional levels in the kidney were decreased by 0.58-fold, 0.47-fold and 0.63-fold in the 0.42, 0.83 and 1.70% CLA treatment groups, respectively (Fig. 2(B)).

Discussion

In the present study, the growth of fish was significantly enhanced by moderate inclusion of CLA (0.42%), but decreased when the level of this particular fatty acid was equal to or above 0.83%. The growth-promoting effects of a moderate level of CLA are consistent with the findings in common carp⁽¹⁴⁾, Pacific white shrimp⁽⁴⁷⁾ and channel catfish⁽¹⁵⁾. On the contrary, some studies have reported the deleterious effects of CLA on the growth performance of fish^(6,8,11). Thus, it can be concluded that the effect of CLA on growth performance varies significantly among different species, and this is probably due to different physiological responses to dietary CLA inclusion for different species^(11,12).

The two non-specific immune parameters, PI and respiratory burst, were significantly higher in fish fed diets with 0.42

and 0.83% CLA compared with the control and other groups. The poor non-specific immunity of fish fed the control and the highest-CLA diet (1.70%) could be due to a too high or low inflammation level of the fish body^(24,25). In the present study, mRNA levels of *COX-2* and *IL-1β* were significantly higher in the liver and kidney of fish fed the control diet with a high amount of linoleic acid (18:2*n*-6). High inclusion of dietary *n*-6 fatty acids have been found to exert deleterious effects on the health of gilthead sea bream by influencing fatty acid composition of immune cells with a high deposition of linoleic acid, altering eicosanoid production, and even chronically increasing the basal expression of certain inflammation-related genes^(26,48–51). Thus, the relatively higher level of inflammation could account for the low non-specific immunological parameters of fish fed the control diet in the present investigation. Moderate dietary CLA (0.42–0.83%) could benefit the immunity of fish through modulating inflammation, which is characterised by transcriptional levels of *COX-2* and *IL-1β*, to a relatively optimum level. However, cytokines are key regulators of the immune system that shape innate and adaptive immune responses⁽²⁴⁾. Scarce expression of *COX-2* and *IL-1β* could be responsible for the relatively worse fish immunity in treatments with the higher level of CLA. Since a positive control (100% fish oil-containing diet) was not included in the present study, it is still unknown whether dietary CLA can attenuate inflammation as strongly as fish oil does or whether dietary CLA can improve immune potential.




Fig. 2. Effects of dietary conjugated linoleic acid (CLA) on relative mRNA expression of fatty acid oxidation-related genes (*PPARα*; □), carnitine palmitoyl transferase I (*CPT1*; ▨) and acyl CoA oxidase (*ACO*; ▩) in the liver (A) and kidneys (B) of juvenile large yellow croaker (*Larimichthys crocea*) fed soyabean oil-based diets. Values are means (n 3), with their standard errors represented by vertical bars. ^{a,b} Mean values for the same gene with unlike letters were significantly different ($P < 0.05$; Tukey's test).

However, it should be admitted that CLA could enhance non-specific immunity by ameliorating high inflammation (COX-2 and IL-1 β) caused by high n -6 fatty acids at least from the results of the present study.

In the present study, no significance was detected in the transcription of *TNF-α* among dietary treatments. This was inconsistent with the findings of Montero *et al.*⁽²⁶⁾ who found that transcription of *TNF-α* was significantly higher in fish fed diets with 100% soyabean oil compared with those fed diets with 100% fish oil, 70% linseed oil or 70% soyabean oil. However, it should be noted that transcription of *TNF-α* was detected at different time points (1 d, 3 d and 7 d) after exposure to a sub-lethal dose of *Photobacterium damsela* subsp. *piscicida* in that study. Increased expression of *TNF-α* and *IL-1β* after exposure to pathogens has been reported in several fish species^(26,45). Thus, it is possible that *TNF-α* was less sensitive than *IL-1β* to dietary CLA without pathogen challenge. Furthermore, different fish species and diet formulation could also account for the inconsistent results.

On the other hand, the immune enhancement by moderate dietary CLA may benefit from its antioxidant capacity. The antioxidant effect of CLA has been observed in many studies of rodents and human subjects^(52–54). In the present study, mRNA expression of fatty acid oxidation-related genes in the liver and kidney declined while hepatic antioxidant capacity increased as dietary CLA level increased to 0.83%. This means that CLA could function as a kind of antioxidant nutrient in the large yellow croaker. Intervention with antioxidant

nutrients (vitamin E, vitamin C, β -carotene and carotenoids) has been shown to enhance the immune response in several fish species^(31,55–59). Antioxidant nutrients are proposed to exert their immune-enhancing effects through suppression of lipid peroxide and/or PGE₂ production according to the findings in mammals^(29,30). In the present study, the expression of *COX-2* and *IL-1β* generally paralleled well with the transcription of fatty acid oxidation-related genes while showing an antagonistic tendency with hepatic antioxidant capacity as dietary CLA increased. However, hepatic antioxidant capacity was not further enhanced in fish fed the diet with the highest level of CLA, which was in accordance with PI and respiratory burst activity. Reactive oxygen species exert a critical role in bacterial killing after bacteria are ingested by phagocytes^(60,61). When fatty acid oxidation was inhibited to a very low level, the normal respiratory burst activity (reactive oxygen species production) could be unavoidably damaged.

In the present study, fish fed the control diet were subject to serious inflammation, characterised by a relatively higher transcription of *COX-2* and *IL-1β*, higher expression of fatty acid oxidation-related genes (*PPARα*, *CPT-I* and *ACO*) and MDA production, as well as significantly lower antioxidant capacity. In accordance, the hepatosomatic index and viserosomatic index were significantly lower in fish fed the control diet. This implies that fish fed the diets without CLA (the control) may suffer hepatic injury and toxicity from serious oxidative stress and inflammation. Indeed, hepatic disease caused by inflammation and oxidative stress has been reported in

considerable studies on rodents⁽¹⁶⁾ and male Japanese medaka⁽²⁷⁾. However, no direct evidence was obtained in the present study, and investigations are needed to verify this hypothesis in further studies.

An increasing lipid content of the whole body and muscle was observed as dietary CLA level increased in the present study. This could result from decreasing fatty acid oxidation, which is reflected by reduced transcription of *PPARα*, *CPT1* and *ACO*, in response to increasing dietary CLA. However, there were no significant differences in liver lipid concentration among dietary treatments. The present results are in accordance with the findings of Kennedy *et al.*⁽¹⁰⁾ who found that muscle lipid content of Atlantic salmon increased as dietary CLA increased and support the fact that dietary CLA had no significant effect on the liver lipid content of catfish⁽⁷⁾, Atlantic salmon⁽¹⁰⁾ or rainbow trout juveniles⁽⁹⁾. In contrast, decreased lipid concentration in the whole body or liver was observed in some other studies^(5,6,9,11). The different physiological effects of CLA observed in the present study and other reports may be attributed to differences in metabolic rate, administered dose of CLA, relative proportion of each isomer in a dietary CLA mixture, or duration of the feeding period, as pointed out by Terpstra⁽⁶²⁾. Furthermore, different diet formulations may be one important cause for the discrepancies in the effects of dietary CLA on lipid deposition. In the present investigation, soyabean oil was used to balance the total amount of oil mixture, with almost equal amount of *n-3* HUFA and ratio of *n-3:n-6* PUFA among the four diets. However, in most previous studies, fish oil was used to acquire equal lipid content, and thus *n-3* HUFA and ratio of *n-3:n-6* PUFA were decreased as dietary CLA increased. The lipid concentration of the whole fish body increased with the increase of dietary *n-3* HUFA in gilthead sea bream⁽⁶³⁾ and large yellow croaker (RT Zuo, QH Ai, KS Mai and W Xu, unpublished results). As dietary *n-3:n-6* PUFA increased, body lipid also increased in gilthead sea bream⁽⁶⁴⁾ and juvenile yellow catfish⁽⁶⁵⁾. Evidence above indicated that lipid-decreasing effects caused by dietary CLA could be attributed to decreased dietary *n-3* HUFA level or *n-3:n-6* PUFA in some previous studies.

In the present study, the total percentages of the main fatty acids were strongly affected by the dietary inclusion of CLA. A significant increase of SFA and decrease of MUFA was observed in the liver and muscle of fish fed diets with increasing amounts of CLA. This was similar to the findings of some previous studies on other fish species^(11,66). Since SFA and MUFA concentrations were equal among experimental diets in the present study, the increased SFA and decreased MUFA in the liver and muscle could be attributed to a low conversion of SFA to MUFA. Indeed, reduced activity of $\Delta 9$ desaturase, a rate-limiting enzyme converting SFA to MUFA, has been found to be suppressed by dietary CLA as pointed out by Valente *et al.*⁽¹²⁾. EPA and DHA profiles in selected tissues of the present experiment showed no significant differences among dietary treatments. This was consistent with the findings of studies by Makol *et al.*⁽⁴⁾ and Tan *et al.*⁽¹¹⁾, but inconsistent with the results of some other studies where increased EPA and DHA levels were found as dietary CLA increased^(6,12,67).

Increased deposition of *n-3* HUFA could result from a higher expression of $\Delta 5$ and $\Delta 6$ desaturases that play critical roles in HUFA biosynthesis^(9,68). In the present study, hepatic ARA concentration increased while *COX-2* expression decreased significantly with the increase in dietary CLA. It was possible that more ARA in the liver of fish fed the control diet participated in eicosanoid production catalysed by *COX-2* and this resulted in the lower ARA deposition in the control treatment. Although PGE_2 concentration was not assayed in serum or other tissues, it is usually believed that PGE_2 content parallels well with *COX-2* transcriptional levels to a large extent^(69–72).

To conclude, a moderate level of dietary CLA could be beneficial for fish growth performance, non-specific immunity and hepatic antioxidant capacity. In the large yellow croaker, dietary CLA may exert beneficial effects through modulating the mRNA expression of inflammation-related genes (*COX-2* and *IL-1β*) and fatty acid oxidation-related genes (*PPARα*, *CPT1* and *ACO*). Future studies are needed to investigate the effects of this particular fatty acid on other metabolism processes such as lipid transportation and distribution in the large yellow croaker.

Acknowledgements

This research was supported by the National Natural Foundation of China (grant no. 30871930 and 31172425).

We thank H. Asino, Q. Y. Duan, J. K. Shentu, Y. W. Luo, R. J. Sun, X. W. Yi and L. Wang for their selfless help during the samplings, Y. F. Zheng for his supplying of essential facilities during the tests of immunological parameters, and X. J. Dong for her help in cloning the core region of *ACO*.

R. Z. designed all experiments, carried out most of experimental work and wrote the manuscript under the direction of project leader Q. A.; K. M. assisted in the experimental design and manuscript revision; W. X. provided all fatty acid composition data.

There are no conflicts of interest to report.

References

1. Diez A, Menoyo D, Pérez-Benavente S, *et al.* (2007) Conjugated linoleic acid affects lipid composition, metabolism and gene expression in gilthead sea bream (*Sparus aurata* L). *J Nutr* **137**, 1363–1369.
2. Belury M (2002) Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. *Annu Rev Nutr* **22**, 505–531.
3. Risérus U, Smedman A, Basu S, *et al.* (2003) CLA and body weight regulation in humans. *Lipids* **38**, 133–137.
4. Makol A, Torrecillas S, Fernandez-Vaquero A, *et al.* (2009) Effect of conjugated linoleic acid on dietary lipids utilization, liver morphology and selected immune parameters in sea bass juveniles (*Dicentrarchus labrax*). *Comp Biochem Physiol* **154B**, 179–187.
5. Twibell RG, Watkins BA & Brown PB (2001) Dietary conjugated linoleic acids and lipid source alter fatty acid composition of juvenile yellow perch, *Perca flavescens*. *J Nutr* **131**, 2322–2328.

6. Twibell RG, Watkins BA, Rogers L, *et al.* (2000) Effects of dietary conjugated linoleic acids on hepatic and muscle lipids in hybrid striped bass. *Lipids* **35**, 155–161.
7. Twibell RG & Wilson RP (2003) Effects of dietary conjugated linoleic acids and total dietary lipid concentrations on growth responses of juvenile channel catfish, *Ictalurus punctatus*. *Aquaculture* **221**, 621–628.
8. Yasmin A, Takeuchi T, Hayashi M, *et al.* (2004) Effect of conjugated linoleic acid and docosahexanoic acids on growth of juvenile *Oreochromis niloticus*. *Fish Sci* **70**, 473–481.
9. Bandarra M, Nunes ML, Andrade AM, *et al.* (2006) Effect of dietary conjugated linoleic acid on muscle, liver and visceral lipid deposition in rainbow trout juveniles (*Oncorhynchus mykiss*). *Aquaculture* **254**, 496–505.
10. Kennedy SR, Campbell PJ, Porter A, *et al.* (2005) Influence of dietary conjugated linoleic acid (CLA) on lipid and fatty acid composition in liver and flesh of Atlantic salmon (*Salmo salar*). *Comp Biochem Physiol* **141**, 168–178.
11. Tan XY, Luo Z, Xie P, *et al.* (2010) Effect of dietary conjugated linoleic acid (CLA) on growth performance, body composition and hepatic intermediary metabolism in juvenile yellow catfish *Pelteobagrus fulvidraco*. *Aquaculture* **310**, 186–191.
12. Valente LMP, Bandarra NM, Figueiredo-Silva A, *et al.* (2007) Conjugated linoleic acid in diets for large size rainbow trout (*Oncorhynchus mykiss*): effects on growth, chemical composition and sensory attributes. *Br J Nutr* **97**, 289–297.
13. Yasmin A & Takeuchi T (2002) Influence of various dietary levels of conjugated linoleic acid (CLA) on juvenile tilapia *Oreochromis niloticus*. *Fish Sci* **68**, Suppl., 991–992.
14. Choi BD, Kang SJ, Ha YL, *et al.* (1999) Accumulation of conjugated linoleic acid (CLA) in tissues of fish fed diets containing various levels of CLA. In *Quality Attributes of Muscle Foods*, pp. 61–71 [YL Xiong, CT Ho and F Shahidi, editors]. New York: Kluwer Academic/Plenum Publishers.
15. Peterson BC, Manning B & Li M (2003) CLA-enriched diets for channel catfish. *Glob Aquac Advocate* **6**, 48–50.
16. Byrne CD (2010) Fatty liver: role of inflammation and fatty acid nutrition. *Prostaglandins Leukot Essent Fatty Acids* **82**, 265–271.
17. Li Y & Watkins BA (1998) Conjugated linoleic acids alter bone fatty acid composition and reduce *ex vivo* prostaglandin E₂ biosynthesis in rats fed *n-6* or *n-3* fatty acids. *Lipids* **33**, 417–425.
18. Kim KH & Park HS (2003) Dietary supplementation of conjugated linoleic acid reduces colon tumor incidence in DMH-treated rats by increasing apoptosis with modulation of biomarkers. *Nutrition* **19**, 772–777.
19. Goodwin JS & Webb DR (1980) Regulation of the immune response by prostaglandins. *Clin Immunol* **15**, 106–122.
20. Park Y & Pariza MW (2007) Mechanisms of body fat modulation by conjugated linoleic acid (CLA). *Food Res Int* **40**, 311–323.
21. Brown JM, Boysen MS, Chung S, *et al.* (2004) Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines. *J Biol Chem* **279**, 26735–26747.
22. Chung S, Brown JM, Provo JN, *et al.* (2005) Conjugated linoleic acid promotes human adipocyte insulin resistance through NFκB-dependent cytokine production. *J Biol Chem* **280**, 38445–38456.
23. Wun T, McKnight H & Tuscano JM (2004) Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. *Leukemia Res* **28**, 179–190.
24. Chabalgoity JA, Baz A, Rial A, *et al.* (2007) The relevance of cytokines for development of protective immunity and rational design of vaccines. *Cytokine Growth Factor Rev* **18**, 195–207.
25. Alfano M & Poli G (2005) Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. *Mol Immunol* **42**, 161–182.
26. Montero D, Mathlouthi F, Tort L, *et al.* (2010) Replacement of dietary fish oil by vegetable oils affects humoral immunity and expression of proinflammatory cytokines genes in gilt-head sea bream *Sparus aurata*. *Fish Shellfish Immunol* **29**, 1073–1081.
27. Yang JH (2010) Perfluorooctanoic acid induces peroxisomal fatty acid oxidation and cytokine expression in the liver of male Japanese medaka (*Oryzias latipes*). *Chemosphere* **81**, 548–552.
28. Zhao ZY, Wu TX, Tang HG, *et al.* (2008) Effect of conjugated linoleic acid on growth, lipid metabolism and liver peroxisome proliferators-activated receptor expression of large yellow croaker (*Pseudosciaena crocea*). *J Food Lipids* **15**, 534–554.
29. Furukawa T, Meydani SN & Blumberg JB (1987) Reversal of age-associated decline in immune responsiveness by dietary glutathione supplementation in mice. *Mech Ageing Dev* **38**, 107–117.
30. Meydani SN, Barklund MP, Liu S, *et al.* (1990) Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. *Am J Clin Nutr* **52**, 557–563.
31. Ai QH, Mai KS, Zhang CX, *et al.* (2004) Effects of dietary vitamin C on growth and immune response of Japanese seabass, *Lateolabrax japonicus*. *Aquaculture* **242**, 489–500.
32. Ai QH, Mai KS, Zhang L, *et al.* (2007) Effects of dietary β-1, 3 glucan on innate immune response of large yellow croaker, *Pseudosciaena crocea*. *Fish Shellfish Immunol* **22**, 394–402.
33. Ai QH, Zhao JZ, Mai KS, *et al.* (2008) Optimal dietary lipid level for large yellow croaker (*Pseudosciaena crocea*) larvae. *Aquacult Nutr* **14**, 515–522.
34. Zhang CX, Ai QH, Mai KS, *et al.* (2008) Dietary lysine requirement of large yellow croaker. *Pseudosciaena crocea R. Aquaculture* **283**, 123–127.
35. Wang J, Ai QH, Mai KS, *et al.* (2010) Effects of dietary ethoxyquin on growth performance and body composition of large yellow croaker *Pseudosciaena crocea*. *Aquaculture* **306**, 80–84.
36. Zuo RT, Ai QH, Mai KS, *et al.* (2012) Effects of dietary *n-3* highly unsaturated fatty acids on growth, nonspecific immunity, expression of some immune related genes and disease resistance of large yellow croaker (*Larmichthys crocea*) following natural infestation of parasites (*Cryptocaryon irritans*). *Fish Shellfish Immunol* **32**, 249–258.
37. Metcalfe LD, Schmitz AA & Pelka JR (1966) Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. *Anal Chem* **38**, 514–515.
38. Pulsford AL, Crampe M, Langston A, *et al.* (1995) Modulatory effects of disease, stress, copper, TBT and vitamin E on the immune system of flatfish. *Fish Shellfish Immunol* **5**, 631–643.
39. Secombes CJ (1990) Isolation of salmonid macrophages and analysis of their killing activity. In *Techniques in Fish Immunology*, pp. 137–154 [JS Stolen, TC Fletcher, DP Anderson, BS Robertsen and WB van Muiswinkel, editors]. Fair Haven, NJ: SOS Publications.
40. Ellis AE (1990) Lysozyme assays. In *Techniques in Fish Immunology*, pp. 101–103 [JS Stolen, TC Fletcher, DP Anderson, BS Robertsen and WB van Muiswinkel, editors]. Fair Haven, NJ: SOS Publications.

41. Bradford M (1976) A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**, 248–254.
42. Aebi H (1984) Catalase *in vitro*. *Methods Enzymol* **105**, 121–127.
43. McCord JM & Fridovich I (1969) Superoxide dismutase: an enzymatic function for erythrocyte. *J Biol Chem* **244**, 6049–6055.
44. Gavino VC, Miller JS, Ikharebha SO, *et al.* (1981) Effects of polyunsaturated fatty acids and antioxidants on lipid peroxidation in tissue cultures. *J Lipid Res* **22**, 763–769.
45. Xie FJ, Zhang ZP, Lin P, *et al.* (2008) Cloning and infection response of tumour-necrosis factor α in large yellow croaker *Pseudosciaena crocea* (Richardson). *J Fish Biol* **73**, 1149–1160.
46. Yao CL, Kong P, Wang ZY, *et al.* (2009) Molecular cloning and expression of MyD88 in large yellow croaker. *Pseudosciaena crocea*. *Fish Shellfish Immunol* **26**, 249–255.
47. Zhong WJ, Zhang SP, Li JF, *et al.* (2011) Effects of dietary replacement of fish oil by conjugated linoleic acid on some meat quality traits of Pacific white shrimp *Litopenaeus vannamei*. *Food Chem* **127**, 1739–1743.
48. Montero D, Kalinowski T, Obach A, *et al.* (2003) Vegetable lipid sources for gilthead seabream (*Sparus aurata*): effects on fish health. *Aquaculture* **225**, 353–370.
49. Farndale BM, Bell JG, Bruce MP, *et al.* (1999) Dietary lipid composition affects blood leucocyte fatty acid compositions and plasma eicosanoid concentrations in European sea bass (*Dicentrarchus labrax*). *Aquaculture* **179**, 335–350.
50. Ganga R, Bell JG, Montero D, *et al.* (2005) Effect of dietary lipids on plasma fatty acid profiles and prostaglandin and leptin production in gilthead seabream (*Sparus aurata*). *Comp Biochem Physiol* **142B**, 410–418.
51. Montero D, Grasso V, Izquierdo MS, *et al.* (2008) Total substitution of fish oil by vegetable oils in gilthead sea bream (*Sparus aurata*) diets: effects on hepatic Mx expression and some immune parameters. *Fish Shellfish Immunol* **24**, 147–155.
52. Hayek MG, Han SN, Wu DY, *et al.* (1999) Dietary conjugated linoleic acid influences the immune response of young and old C57BL/6NCrLBR mice. *J Nutr* **129**, 32–38.
53. Flintoff-Dye NL & Omaye ST (2005) Antioxidant effects of conjugated linoleic acid isomers in isolated human low-density lipoproteins. *Nutr Res* **25**, 1–12.
54. Bergamo P, Maurano F & Rossi M (2007) Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress. *Free Radical Bio Med* **43**, 71–79.
55. Lin YH & Shiau SY (2005) Dietary vitamin E requirement of grouper, *Epinephelus malabaricus*, at two lipid levels, and their effects on immune responses. *Aquaculture* **248**, 235–244.
56. Ai QH, Mai KS, Tan BP, *et al.* (2006) Effects of dietary vitamin C on survival, growth, and immunity of large yellow croaker, *Pseudosciaena crocea*. *Aquaculture* **261**, 327–336.
57. Wang ZL, Mai KS, Liufu ZG, *et al.* (2006) Effect of high dietary intakes of vitamin E and *n*-3 HUFA on immune responses and resistance to *Edwardsiella tarda* challenge in Japanese flounder (*Paralichthys olivaceus*, Temminck and Schlegel). *Aquacult Res* **37**, 681–692.
58. Rodríguez A, Cuesta A, Esteban MÁ, *et al.* (2004) The effect of dietary administration of the fungus *Mucor circinelloides* on non-specific immune responses of gilthead seabream. *Fish Shellfish Immunol* **16**, 241–249.
59. Amar EC, Kiron V, Akutsu T, *et al.* (2012) Resistance of rainbow trout *Oncorhynchus mykiss* to infectious hematopoietic necrosis virus (IHNV) experimental infection following ingestion of natural and synthetic carotenoids. *Aquaculture* **330–333**, 148–155.
60. Sharp GJE, Nagelkeke LAJ & Secombes CJ (1991) Generation of reactive oxygen species from fish macrophages and their role in the killing of fish bacterial pathogens. *Dev Comp Immunol* **15**, 70–76.
61. Sharp GJE & Secombes CJ (1993) The role of reactive oxygen species in the killing of the bacterial fish pathogen *Aeromonas salmonicida* by rainbow trout macrophages. *Fish Shellfish Immunol* **3**, 119–129.
62. Terpstra AHM (2001) Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. *J Nutr* **131**, 2067–2068.
63. Kalogeropoulos N, Alexios MN & Henderson RJ (1992) Effects of dietary soybean and cod-liver oil levels on growth and body composition of gilthead seabream (*Sparus aurata*). *Aquaculture* **104**, 293–308.
64. Robaina L, Izquierdo MS, Moyano FJ, *et al.* (1998) Increase of the dietary *n*-3/*n*-6 fatty acid ratio and addition of phosphorus improves liver histological alterations induced by feeding diets containing soybean meal to gilthead seabream, *Sparus aurata*. *Aquaculture* **161**, 281–293.
65. Tan XY, Luo Z, Xie P, *et al.* (2009) Effect of dietary linolenic acid/linoleic acid ratio on growth performance, hepatic fatty acid profiles and intermediary metabolism of juvenile yellow catfish *Pelteobagrus fulvidraco*. *Aquaculture* **296**, 96–101.
66. Dos Santos LD, Furuya WM, da Silva LCR, *et al.* (2011) Dietary conjugated linoleic acid (CLA) for finishing Nile tilapia. *Aquacult Nutr* **17**, 70–81.
67. Manning BB, Li MH, Robinson EH, *et al.* (2006) Enrichment of channel catfish (*Ictalurus punctatus*) fillets with conjugated linoleic acid and omega-3 fatty acids by dietary manipulation. *Aquaculture* **261**, 337–342.
68. Pereira SL, Leonard AE & Mukerji P (2003) Recent advances in the study of fatty acid desaturases from animals and lower eucaryotes. *Prostaglandins Leukot Essent Fatty Acids* **68**, 97–106.
69. Schuligoi R, Ulcar R, Peskar BA, *et al.* (2003) Effect of endotoxin treatment on the expression on cyclooxygenase-2 and prostaglandin synthesis in spinal cord dorsal root ganglia, and skin of rats. *Neuroscience* **116**, 1043–1052.
70. Ayalasonmayajula SP, Amrite AC & Kompella UB (2004) Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. *Eur J Pharmacol* **498**, 275–278.
71. Candelario-Jalil E, Akundi RS, Bhatia HS, *et al.* (2006) Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E₂ production. *J Neuroimmunol* **174**, 39–51.
72. Dhillon JK, Su XR & Liu ZM (2010) Effects of RU486 on cyclooxygenase-2 gene expression, prostaglandin F_{2α} synthesis and ovulation in *Xenopus laevis*. *Gen Comp Endocr* **165**, 78–82.